Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC)

IMUNOTERAPIA EM CÂNCER DE MAMA ESTUDO NEGATIVO DE UMA POSSÍVEL INTELIGENTE COMBINAÇÃO DE  ERIBULINA COM PEMBROLIZUMAB 















Comentários

Postar um comentário

Postagens mais visitadas deste blog

Imagem
 https://sabcs.onlineeventpro.freeman.com/posters/25581279/Efficacy-and-tolerability-of-neoadjuvant-Pertuzumab-Trastuzumab-and-weekly-Paclitaxel-in-Locally-advanced-Her-2-positive-Breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582333/Phase-II-pilot-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-HER-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-HER-2-directed https://sabcs.onlineeventpro.freeman.com/posters/25581672/HER2CLIMB-02-A-randomized-double-blind-phase-3-study-of-tucatinib-or-placebo-with-T-DM1-for-unresectable-locally-advanced-or-metastatic-HER2-breast-cancer          
Leia mais